Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 March 2023 | Story Jóhann Thormählen | Photo Supplied
Nomsa Mathontsi is a senior member of the Kovsie women’s football team and has played in two Varsity Football and three USSA tournaments.

Nomsa Mathontsi senior member of the University of the Free State (UFS) Women’s Football team has, despite enormous challenges excelled and achieved remarkable heights on and off the field.

Ms Mathontsi has been an avid sportsperson from an early age. Among her many extraordinary achievements the talented Ms Mathontsi has also been on the South African Women’s National Soccer squad Banyana Banyana.

What many may not know though, is that this is notwithstanding the obstacle Ms Mathontsi overcame in order to reach such heights. The Kovsie striker has limited hearing in her right ear and received a cochlear implant before she began her UFS journey in 2018.

I got affected when I was really young. I was doing athletics. This one time I had a very hectic race, which blocked my right ear –

At the University of the Free State Kovsie Health takes into account the medical history of its’ high-performance athletes who are closely monitored with the aim of achieving optimal performance. As in the case of Ms Mathonsi it is most important that the medical practitioner, Dr Gerhard Jansen, and his team at Kovsie Health take into consideration her medical history. 

Kovsie Health provides a range of services to the UFS football programme that include: medical screenings; injury diagnosis; treatment; and rehabilitation. 

Compulsory medicals

“I got affected when I was really young. I was doing athletics. This one time I had a very hectic race, which blocked my right ear.

“At first my family thought it was going to be OK, until we realised it was extremely serious and we had to do medicals,” the versatile player says.

Ms Mathontsi, a BAdmin student in Economic and Management Sciences has an implant in her skull but cannot play with her hearing device.

“Even the implant itself can be dangerous. If someone hits me with an elbow or something hard or (on the) head, it will hurt.”

It is compulsory for all UFS football players to take the South African Football Association medicals. Kovsie Health assists players in this process. This is conducted before each new season and include a basic medical, family and practice history, basis line tests, injury assessments etc.

According to Jansen, Kovsie Health needs to be aware of Mathontsi’s medical history so that they may make informed decisions and provide guidance. We will document it and if she should get concussion you will have to take it into account. We for instance know we shouldn’t see a loss of hearing as a negative sign.”

Special Kovsie football family

Mathontsi has represented the UFS in two Varsity Football campaigns, three USSA tournaments and plays in the Free State Sasol League.

Although she hasn’t made her international debut, she received two call-ups to the South African women’s squad and trained with Banyana Banyana.

The number 8 loves her UFS football family and says she has also learnt to balance sport and university.

“I think it is the bond and relationships we have with each other on and off the field that makes it special.

“I have learnt a lot in terms of leadership and how to take leadership as a senior player in the team.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept